CARDIOVASCULAR DISEASE DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-121136 |   Pharmaceuticals

Historical data: 2017 - 2023

Forecast period: 2025 - 2031

Quantitative units: Revenue in USD million and CAGR from 2025 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Cardiovascular Disease Drugs Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL CARDIOVASCULAR DISEASE DRUGS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL CARDIOVASCULAR DISEASE DRUGS MARKET

7.1 GLOBAL CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)

8.1 GLOBAL CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

8.2 GLOBAL CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

9.1 GLOBAL CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

9.2 GLOBAL CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

10.1 GLOBAL CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)

10.2 GLOBAL CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)

11.1 NORTH AMERICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

11.2 NORTH AMERICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

11.3 NORTH AMERICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

11.4 NORTH AMERICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

11.5 NORTH AMERICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

11.6 NORTH AMERICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

12.1 EUROPE CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

12.2 EUROPE CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

12.3 EUROPE CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

12.4 EUROPE CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

12.5 EUROPE CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

12.6 EUROPE CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

13.1 ASIA PACIFIC CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

13.2 ASIA PACIFIC CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

13.3 ASIA PACIFIC CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

13.4 ASIA PACIFIC CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

13.5 ASIA PACIFIC CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

13.6 ASIA PACIFIC CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

14.1 LATIN AMERICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>

14.2 LATIN AMERICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

14.3 LATIN AMERICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

14.4 LATIN AMERICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

14.5 LATIN AMERICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

14.6 LATIN AMERICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>

16.1 AstraZeneca

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Johnson & Johnson

16.3 Pfizer

16.4 Sanofi

16.5 Merck

16.6 Daiichi Sankyo Company Limited

16.7 Novartis

16.8 Bayer

16.9 Takeda Pharmaceutical

16.10 Roche

16.11 United Therapeutics Corporation

16.12 Actelion Pharmaceuticals

16.13 Boehringer Ingelheim

16.14 Astellas Pharma

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Cardiovascular Disease Drugs Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Units)
Cardiovascular Disease Drugs Market Segment Percentages, By Type, 2020 (%)
- Heparin
- Coumadin
- Sectral
- Zebeta
- Lopressor
- Toprol XL
- Norvasc
- Lotrel
- Others

Cardiovascular Disease Drugs Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Units)
Cardiovascular Disease Drugs Market Segment Percentages, By Application, 2020 (%)
- Asischemic Heart Disease
- Dyslipidemia
- Stroke
- Thrombosis
- Atherosclerosis
- Coronary Artery Diseases
- Peripheral Artery Disease
- Others

Companies

AstraZeneca
Johnson & Johnson
Pfizer
Sanofi
Merck
Daiichi Sankyo Company Limited
Novartis
Bayer
Takeda Pharmaceutical
Roche
United Therapeutics Corporation
Actelion Pharmaceuticals
Boehringer Ingelheim
Astellas Pharma

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.